- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07585058
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation in Acute Ischemic Stroke (SeeBCI)
Safety and Efficacy of Early Non-invasive Brain-Computer Interface-Based Rehabilitation Training in Patients With Acute Ischemic Stroke: The SeeBCI Study
This is a single-center, prospective, randomized, sham-controlled pilot clinical study designed to evaluate the efficacy, safety, and feasibility of early non-invasive electroencephalography-based brain-computer interface (EEG-BCI) rehabilitation training in patients with acute ischemic stroke.
Eligible participants are adults aged 18 to 80 years with acute ischemic stroke, unilateral upper extremity motor impairment on the dominant-hand side, a baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score of 10 to 50, and confirmed clinical stability 48 to 72 hours after stroke onset.
Participants will be randomly assigned in a 1:1 ratio to receive either real EEG-BCI training plus standard early rehabilitation or sham BCI training plus standard early rehabilitation. Both groups will receive 10 days of training, with two sessions per day and approximately 30 minutes per session.
The primary outcome is the change in FMA-UE score from baseline to 30 days after randomization. Secondary outcomes include changes in FMA-UE, Action Research Arm Test (ARAT), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and modified Rankin Scale (mRS). Safety outcomes include symptomatic intracranial hemorrhage, any intracranial hemorrhage, neurological deterioration, seizures, falls, cardiovascular events, and training-related adverse events.
This pilot study aims to provide preliminary evidence regarding the feasibility, safety, and potential efficacy of early EEG-BCI rehabilitation after acute ischemic stroke and to inform the design of future multicenter randomized controlled trials.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Wang Chen, MD
- Numéro de téléphone: +86 531 68773274
- E-mail: chenwang@sph.com.cn
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18 to 80 years.
- Diagnosis of acute ischemic stroke.
- Stroke onset to randomization within 48 to 72 hours.
- Meets predefined clinical stability criteria before randomization.
- Unilateral upper extremity motor impairment on the dominant-hand side.
- Baseline Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) score between 10 and 50.
- Pre-stroke modified Rankin Scale (mRS) score ≤2.
- Written informed consent obtained from the participant or legally authorized representative.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Real EEG-BCI Training + Standard Early Rehabilitation
Participants will receive real electroencephalography-based brain-computer interface (EEG-BCI) training combined with standard early rehabilitation. The EEG-BCI training uses upper extremity motor imagery or motor attempt tasks with real-time decoding of motor intention and virtual hand feedback. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Non-invasive EEG-based brain-computer interface training combined with standard early rehabilitation. The intervention includes EEG signal acquisition, motor intention decoding, and real-time virtual hand feedback. Participants perform upper extremity motor imagery or motor attempt tasks. Training is delivered twice daily for approximately 30 minutes per session for 10 consecutive days. Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. |
|
Comparateur factice: Sham BCI Training + Standard Early Rehabilitation
Participants will receive sham BCI training combined with standard early rehabilitation. The sham procedure will match the real EEG-BCI training in appearance, frequency, duration, and workflow, but the feedback will not be generated by real-time EEG-based motor intention decoding. Training will be performed twice daily for approximately 30 minutes per session over 10 consecutive days (20 sessions in total). |
Participants in both groups will receive standard early rehabilitation according to clinical practice, including appropriate physical therapy, occupational therapy, task-oriented training, positioning, and other routine rehabilitation interventions. Sham BCI training designed to maintain participant masking. The procedure matches real EEG-BCI training in device setup, training environment, frequency, duration, and workflow, but the feedback is not linked to the participant's real-time EEG motor intention decoding. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score From Baseline to Day 30
Délai: Baseline to Day 30 after randomization
|
The primary outcome is the change in FMA-UE score from baseline (T0) to 30 days after randomization. The FMA-UE evaluates upper extremity motor function after stroke, with scores ranging from 0 to 66. Higher scores indicate better upper extremity motor function. Change score is calculated as the FMA-UE score at Day 30 minus the baseline FMA-UE score. |
Baseline to Day 30 after randomization
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fugl-Meyer Assessment of the Upper Extremity (FMA-UE) Score
Délai: Baseline, Day 10, Day 30, and Day 90
|
Upper extremity motor function will be assessed using the FMA-UE. The total score ranges from 0 to 66, with higher scores indicating better motor function. |
Baseline, Day 10, Day 30, and Day 90
|
|
Action Research Arm Test (ARAT) Score
Délai: Baseline, Day 30, and Day 90
|
Upper extremity activity performance will be assessed using the ARAT. The total score ranges from 0 to 57, with higher scores indicating better upper limb functional ability. |
Baseline, Day 30, and Day 90
|
|
National Institutes of Health Stroke Scale (NIHSS) Score
Délai: Baseline, Day 10, and Day 30
|
Neurological impairment will be assessed using the NIHSS. Scores range from 0 to 42, with higher scores indicating greater neurological deficit. |
Baseline, Day 10, and Day 30
|
|
Modified Rankin Scale (mRS) Score
Délai: Day 90
|
Global functional outcome will be assessed using the modified Rankin Scale. Scores range from 0 to 6, with higher scores indicating greater disability. |
Day 90
|
|
Modified Barthel Index (MBI) Score
Délai: Day 30 and Day 90
|
Activities of daily living will be assessed using the Modified Barthel Index. Higher scores indicate better functional independence. |
Day 30 and Day 90
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Training Completion Rate
Délai: During the 10-day intervention period
|
Feasibility outcome defined as the proportion of completed EEG-BCI or sham BCI training sessions among the planned 20 sessions. |
During the 10-day intervention period
|
|
Effective Training Duration
Délai: During the 10-day intervention period
|
Feasibility outcome defined as the cumulative duration of completed valid BCI training sessions during the intervention period. |
During the 10-day intervention period
|
|
EEG Signal Quality and BCI Performance Metrics
Délai: During the 10-day intervention period
|
Feasibility outcome assessing EEG acquisition quality and available BCI performance metrics, including signal quality and classification accuracy when available. |
During the 10-day intervention period
|
|
Follow-up completion rate
Délai: Through Day 90
|
Feasibility outcome defined as the proportion of randomized participants who complete scheduled outcome assessments through Day 90. |
Through Day 90
|
|
Protocol deviation rate
Délai: From randomization through Day 90
|
Feasibility outcome defined as the proportion of participants with one or more protocol deviations. |
From randomization through Day 90
|
|
Incidence of symptomatic intracranial hemorrhage
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of symptomatic intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of any intracranial hemorrhage
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of any type of intracranial hemorrhage after randomization. |
From baseline through Day 90
|
|
Incidence of neurological deterioration
Délai: From baseline through Day 90
|
Safety outcome defined as clinically relevant neurological worsening after randomization, such as an increase in NIHSS score of 4 or more points without another clear explanation. |
From baseline through Day 90
|
|
Incidence of seizures
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of seizure events after randomization. |
From baseline through Day 90
|
|
Incidence of Falls or Injuries
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of falls during the study period. |
From baseline through Day 90
|
|
Incidence of Cardiovascular and Vital Sign Events
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of clinically relevant blood pressure instability or cardiac arrhythmia events during the study period. |
From baseline through Day 90
|
|
Incidence of training-related discomfort
Délai: During the 10-day intervention period
|
Safety outcome defined as the occurrence of training-related discomfort, including fatigue, headache, dizziness, nausea, skin irritation, or other discomfort associated with the intervention. |
During the 10-day intervention period
|
|
Incidence of serious adverse events
Délai: From baseline through Day 90
|
Safety outcome defined as the occurrence of serious adverse events (SAEs), including death, life-threatening events, hospitalization or prolongation of hospitalization, persistent or significant disability, or other medically important events. |
From baseline through Day 90
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: QinJian Sun, MD, Shandong Provincial Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SWYX.NO.2026-1053
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .